Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma

Adam Sperling • 4 Jun 2023
ASCO 2023
Multiple Myeloma CAR-T PHE885

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the benefits of PHE885, a BCMA CAR-T therapy manufactured in less than two days using the T-Charge platform, explaining that these CAR T-cells can get to the patient faster and expand in the patient, thereby preserving T-cell stemness. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Adam Sperling

1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023
1:58
Clonal hematopoiesis in multiple myeloma and implications for therapy
Adam Sperling • 27 Sep 2023
2:05
Novel CAR-T constructs being explored in myeloma: T-Charge platform
Adam Sperling • 27 Sep 2023
0:36
Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma
Adam Sperling • 4 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals